{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:04:40Z","timestamp":1790593480512,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.molpha.2026.100142","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:53:22Z","timestamp":1784678002000},"page":"100142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Promotion of tumor cell senescence by the antibody\u2013drug conjugate, sacituzumab govitecan"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-4936","authenticated-orcid":false,"given":"Eesha","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4886-6615","authenticated-orcid":false,"given":"Melanie","family":"Sinanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshan","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0437-4934","authenticated-orcid":false,"given":"David A.","family":"Gewirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.molpha.2026.100142_bib1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates\u2014an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2012drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.molpha.2026.100142_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.molpha.2026.100142_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/fon-2020-0163","article-title":"TROPiCS-02: a phase III study investigating sacituzumab govitecan in the treatment of HR+\/HER2- metastatic breast cancer","volume":"16","author":"Rugo","year":"2020","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.molpha.2026.100142_bib5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.molpha.2026.100142_bib6","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2147\/OTT.S162447","article-title":"Targeting Trop-2 in solid tumors: future prospects","volume":"12","author":"Zaman","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"48","key":"10.1016\/j.molpha.2026.100142_bib7","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.molpha.2026.100142_bib8","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.3390\/molecules26237294","article-title":"A new kid on the block: sacituzumab govitecan for the treatment of breast cancer and other solid tumors","volume":"26","author":"Pavone","year":"2021","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.molpha.2026.100142_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.molpha.2026.100142_bib10","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"5A","key":"10.1016\/j.molpha.2026.100142_bib11","first-page":"3499","article-title":"Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis","volume":"18","author":"Voigt","year":"1998","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.molpha.2026.100142_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1158\/1535-7163.MCT-23-0437","article-title":"Improving intracellular delivery of an antibody\u2013drug conjugate targeting carcinoembryonic antigen increases efficacy at clinically relevant doses in vivo","volume":"23","author":"Nessler","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.molpha.2026.100142_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody-drug conjugates: navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.molpha.2026.100142_bib15","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.molpha.2026.100142_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","article-title":"Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates","volume":"21","author":"Khera","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-023-00573-8","article-title":"Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan","volume":"9","author":"Zhao","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"16","key":"10.1016\/j.molpha.2026.100142_bib18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.molpha.2026.100142_bib19","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.molpha.2026.100142_bib20","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5_Supplement","key":"10.1016\/j.molpha.2026.100142_bib21","doi-asserted-by":"crossref","first-page":"GS1","DOI":"10.1158\/1538-7445.SABCS22-GS1-11","article-title":"Abstract GS1-11: sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (Pts) with HR+\/HER2\u2013 metastatic breast cancer (mBC)","volume":"83","author":"Rugo","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s44276-024-00106-1","article-title":"Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1\u221728 polymorphism: a systematic review and meta-analysis","volume":"2","author":"Sultana","year":"2024","journal-title":"BJC Rep"},{"key":"10.1016\/j.molpha.2026.100142_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1447280","article-title":"Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back","volume":"15","author":"Rossi","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2012.08.004","article-title":"Irinotecan induces senescence and apoptosis in colonic cells in vitro","volume":"214","author":"Rudolf","year":"2012","journal-title":"Toxicol Lett"},{"issue":"7","key":"10.1016\/j.molpha.2026.100142_bib25","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3390\/cancers12071815","article-title":"The premature senescence in breast cancer treatment strategy","volume":"12","author":"Milczarek","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molpha.2026.100142_bib26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2147\/IJN.S435407","article-title":"Research progress of SN38 drug delivery system in cancer treatment","volume":"19","author":"Qi","year":"2024","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"10.1016\/j.molpha.2026.100142_bib27","first-page":"1876","article-title":"DNA damage is able to induce senescence in tumor cells in vitro and in vivo","volume":"62","author":"te Poele","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.molpha.2026.100142_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151482","article-title":"Comparative analysis of senescence induction by different chemotherapeutic agents in HCT116 colon cancer cells","volume":"752","author":"Pioger","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.molpha.2026.100142_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117634","article-title":"The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan","volume":"181","author":"Sallbach","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10.1016\/j.molpha.2026.100142_bib30","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/nprot.2009.191","article-title":"Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo","volume":"4","author":"Debacq-Chainiaux","year":"2009","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.molpha.2026.100142_bib31","first-page":"753","article-title":"TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2\/STAT3 signaling pathway","volume":"41","author":"Hou","year":"2018","journal-title":"Oncol Rep"},{"issue":"3\u20134","key":"10.1016\/j.molpha.2026.100142_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2014","journal-title":"Genes Cancer"},{"issue":"24","key":"10.1016\/j.molpha.2026.100142_bib33","doi-asserted-by":"crossref","DOI":"10.21037\/atm-22-5976","article-title":"A literature review of the promising future of TROP2: a potential drug therapy target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.molpha.2026.100142_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"issue":"43","key":"10.1016\/j.molpha.2026.100142_bib35","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.18632\/oncotarget.27766","article-title":"Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer","volume":"11","author":"Cardillo","year":"2020","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.molpha.2026.100142_bib36","doi-asserted-by":"crossref","DOI":"10.31083\/FBL39310","article-title":"Interrogating the involvement of autophagy, senescence, and the immune system in the actions of sacituzumab govitecan as an anticancer agent","volume":"30","author":"Sinanian","year":"2025","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"10","key":"10.1016\/j.molpha.2026.100142_bib37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41419-024-07131-5","article-title":"O-GlcNAcylation inhibition redirects the response of colon cancer cells to chemotherapy from senescence to apoptosis","volume":"15","author":"Loison","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.18632\/oncotarget.2774","article-title":"Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1","volume":"6","author":"Jonch\u00e8re","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.molpha.2026.100142_bib39","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1158\/1078-0432.CCR-04-1462","article-title":"Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response","volume":"11","author":"Elmore","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.molpha.2026.100142_bib40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bcp.2018.12.013","article-title":"Tumor cell escape from therapy-induced senescence","volume":"162","author":"Saleh","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.molpha.2026.100142_bib41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1667\/RR14202.1","article-title":"Radiosensitization by PARP inhibition in DNA repair proficient and deficient tumor cells: proliferative recovery in senescent cells","volume":"185","author":"Alotaibi","year":"2016","journal-title":"Radiat Res"},{"issue":"7","key":"10.1016\/j.molpha.2026.100142_bib42","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-04-1270","article-title":"Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers","volume":"65","author":"Roberson","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.molpha.2026.100142_bib43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/cancers12040822","article-title":"Therapy-induced senescence: an \u201cold\u201d friend becomes the enemy","volume":"12","author":"Saleh","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.molpha.2026.100142_bib44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1006\/bbrc.1998.9832","article-title":"DNA topoisomerase inhibitors induce reversible senescence in normal human fibroblasts","volume":"253","author":"Michishita","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.molpha.2026.100142_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1189015","article-title":"Cellular senescence: a double-edged sword in cancer therapy","volume":"13","author":"Xiao","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.molpha.2026.100142_bib46","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20210079","article-title":"Expression of therapy-induced senescence markers in breast cancer samples upon incomplete response to neoadjuvant chemotherapy","volume":"41","author":"Saleh","year":"2021","journal-title":"Biosci Rep"},{"issue":"4","key":"10.1016\/j.molpha.2026.100142_bib47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/cancers15041279","article-title":"P21 overexpression promotes cell death and induces senescence in human glioblastoma","volume":"15","author":"Mansour","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib48","doi-asserted-by":"crossref","first-page":"144","DOI":"10.18632\/oncotarget.28559","article-title":"Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas","volume":"15","author":"Cardillo","year":"2024","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.molpha.2026.100142_bib49","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1091\/mbc.e11-10-0884","article-title":"Lamin B1 loss is a senescence-associated biomarker","volume":"23","author":"Freund","year":"2012","journal-title":"Mol Biol Cell"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"4","key":"10.1016\/j.molpha.2026.100142_bib51","first-page":"273","article-title":"Therapy-induced senescent tumor cells in cancer relapse","volume":"3","author":"Song","year":"2023","journal-title":"J Natl Cancer Cent"},{"issue":"8","key":"10.1016\/j.molpha.2026.100142_bib52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41568-019-0156-2","article-title":"Unmasking senescence: context-dependent effects of SASP in cancer","volume":"19","author":"Faget","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.molpha.2026.100142_bib53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.resinv.2025.05.012","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancers","volume":"63","author":"Murase","year":"2025","journal-title":"Respir Investig"},{"issue":"3","key":"10.1016\/j.molpha.2026.100142_bib54","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.molpha.2026.100142_bib55","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/15384101.2024.2364579","article-title":"Therapy-induced senescence is finally escapable, what is next?","volume":"23","author":"Saleh","year":"2024","journal-title":"Cell Cycle"},{"issue":"15","key":"10.1016\/j.molpha.2026.100142_bib56","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3390\/cells13151281","article-title":"Therapy-induced cellular senescence: potentiating tumor elimination or driving cancer resistance and recurrence?","volume":"13","author":"Liu","year":"2024","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.molpha.2026.100142_bib57","first-page":"485","article-title":"The senescence-associated secretory phenotype (SASP) in the challenging future of cancer therapy and age-related diseases","volume":"9","author":"Cuollo","year":"2020","journal-title":"Biology (Basel)"},{"issue":"6","key":"10.1016\/j.molpha.2026.100142_bib58","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","article-title":"Hallmarks of cellular senescence","volume":"28","author":"Hernandez-Segura","year":"2018","journal-title":"Trends Cell Biol"},{"issue":"6","key":"10.1016\/j.molpha.2026.100142_bib59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccr.2012.04.027","article-title":"p53-Mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer","volume":"21","author":"Jackson","year":"2012","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.molpha.2026.100142_bib60","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/cells14130942","article-title":"Molecular regulation of SASP in cellular senescence: therapeutic implications and translational challenges","volume":"14","author":"Klepacki","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.molpha.2026.100142_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.966441","article-title":"The BET inhibitor\/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer","volume":"12","author":"Finnegan","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.molpha.2026.100142_bib62","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/molpharm.121.000354","article-title":"Senolytic-mediated elimination of head and neck tumor cells induced into senescence by cisplatin","volume":"101","author":"Ahmadinejad","year":"2022","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.molpha.2026.100142_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114765","article-title":"Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy","volume":"193","author":"Carpenter","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.molpha.2026.100142_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116385","article-title":"Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer","volume":"226","author":"Carpenter","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"19","key":"10.1016\/j.molpha.2026.100142_bib65","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.4161\/cc.8.19.9758","article-title":"Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models","volume":"8","author":"Sabisz","year":"2009","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib66","article-title":"Escape from senescence: revisiting cancer therapeutic strategies","volume":"9","author":"Zampetidis","year":"2022","journal-title":"Mol Cell Oncol"},{"issue":"11","key":"10.1016\/j.molpha.2026.100142_bib67","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.3390\/biomedicines11113066","article-title":"The combination of radiation with PARP inhibition enhances senescence and sensitivity to the senolytic, navitoclax, in triple negative breast tumor cells","volume":"11","author":"Softah","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib68","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1038\/s41467-019-10460-1","article-title":"Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","volume":"10","author":"Fleury","year":"2019","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.molpha.2026.100142_bib69","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.3390\/ijms21176084","article-title":"Improved autophagic flux in escapers from doxorubicin-induced senescence\/polyploidy of breast cancer cells","volume":"21","author":"Bojko","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib70","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ygyno.2011.03.002","article-title":"High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody","volume":"122","author":"Varughese","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.molpha.2026.100142_bib71","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.molpha.2026.100142_bib72","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2019.11.018","article-title":"In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma","volume":"156","author":"Han","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.molpha.2026.100142_bib74","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.ccell.2025.05.015","article-title":"Senescence in cancer","volume":"43","author":"Colucci","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molpha.2026.100142_bib75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fonc.2018.00164","article-title":"Non-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy","volume":"8","author":"Saleh","year":"2018","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.molpha.2026.100142_bib76","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2174\/1389450116666150825113500","article-title":"Is senescence reversible?","volume":"17","author":"Chakradeo","year":"2016","journal-title":"Curr Drug Targets"},{"issue":"6","key":"10.1016\/j.molpha.2026.100142_bib77","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","article-title":"Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence","volume":"11","author":"Duy","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.molpha.2026.100142_bib78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular senescence promotes adverse effects of chemotherapy and cancer relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.molpha.2026.100142_bib79","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/ijc.25482","article-title":"Survivin and escaping in therapy-induced cellular senescence","volume":"128","author":"Wang","year":"2011","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.molpha.2026.100142_bib80","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-18-3437","article-title":"Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy","volume":"79","author":"Saleh","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.molpha.2026.100142_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.04.003","article-title":"Senescent cell clearance by the immune system: emerging therapeutic opportunities","volume":"40","author":"Prata","year":"2018","journal-title":"Semin Immunol"},{"issue":"3","key":"10.1016\/j.molpha.2026.100142_bib82","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cells9030671","article-title":"Immune clearance of senescent cells to combat ageing and chronic diseases","volume":"9","author":"Song","year":"2020","journal-title":"Cells"},{"issue":"18","key":"10.1016\/j.molpha.2026.100142_bib83","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1002\/1878-0261.13268","article-title":"Cellular senescence and the tumour microenvironment","volume":"16","author":"Takasugi","year":"2022","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2017.49","article-title":"Tumor cell senescence response produces aggressive variants","volume":"3","author":"Yang","year":"2017","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.molpha.2026.100142_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.759761","article-title":"The paradoxical role of cellular senescence in cancer","volume":"9","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"10.1016\/j.molpha.2026.100142_bib86","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41416-022-01787-6","article-title":"Considering therapy-induced senescence as a mechanism of tumour dormancy contributing to disease recurrence","volume":"126","author":"Saleh","year":"2022","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.molpha.2026.100142_bib87","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/1878-0261.12761","article-title":"Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL -BAX interaction","volume":"14","author":"Saleh","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.molpha.2026.100142_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.564108","article-title":"Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent","volume":"11","author":"Mohamad Anuar","year":"2020","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.molpha.2026.100142_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100689","article-title":"Strategies to reduce the on-target platelet toxicity of Bcl-XL inhibitors: PROTACs, SNIPERs and prodrug-based approaches","volume":"23","author":"Negi","year":"2022","journal-title":"Chembiochem"},{"issue":"6","key":"10.1016\/j.molpha.2026.100142_bib90","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/cancers14061460","article-title":"Taking advantage of the senescence-promoting effect of olaparib after X-ray and proton irradiation using the senolytic drug, ABT-263","volume":"14","author":"Huart","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.molpha.2026.100142_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-47488-5","article-title":"Deruxtecan-based antibody\u2013drug-conjugates induce senescence in HER2-positive breast cancer","volume":"16","author":"Vezzoli","year":"2026","journal-title":"Sci Rep"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X26000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X26000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:31:36Z","timestamp":1790591496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X26000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0026895X26000428"],"URL":"https:\/\/doi.org\/10.1016\/j.molpha.2026.100142","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promotion of tumor cell senescence by the antibody\u2013drug conjugate, sacituzumab govitecan","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molpha.2026.100142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100142"}}